American Oriental Bioengineering, Inc. Announces Strong Fourth Quarter Orders for GLP Products.

* As of September 24, the Company has received over $6 million in Initial Orders for GLP's Jinji Series of Products for the Fourth Quarter

* The Company Anticipates a further Increase in Order Momentum for GLP Products

NEW YORK -- American Oriental Bioengineering, Inc. (AMEX: AOB), a leading manufacturer and distributor of plant-based pharmaceutical and nutraceutical products in China, today announced GLP has received over $6.0 million in orders for its Jinji Series of products which are expected to be delivered during the fourth quarter.

By leveraging AOB's marketing methodologies, its expanded distribution points and new advertising and marketing campaigns, AOB has begun to see an accelerating pace of business for GLP products. Specifically, the Company hired Ms. Ni Ping, a well known and recognized Chinese celebrity to endorse the Jinji Series of products which targets women's health. Additionally, AOB has implemented a comprehensive training program geared to further educating GLP salespeople and improving the overall level of sales execution. GLP's position in the market is strengthening as the products now have nationwide access to China through AOB's 100,000 distribution points.

"We are very pleased to see a further increase in revenue from our integration of GLP since April," commented Mr. Tony Liu, Chairman and Chief Executive Officer of AOB. "This level of order activity prior to the start of a quarter represents a record for GLP and we are comfortable with our manufacturing capacity to address further anticipated revenue growth. Strong demand for the products has necessitated AOB to manufacture during the China National Day Holiday, a time when many facilities are closed. We remain committed to establishing the Jinji Series as a top three brand in women's health in China and having the brand contribute significantly to AOB's total revenue."

About American Oriental Bioengineering Inc.

American Oriental Bioengineering, Inc. is engaged in the development and production of plant-based pharmaceutical products and plant-based nutraceutical products widely distributed throughout China. For more information, visit http://www.bioaobo.com.

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.